GlassScriptPhysician profile
John R Willard
NPI 1528124369
$6,377.67
in general payments reported to CMS, 2019-2025
46 companies · $877 in 2025
The $877 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $873 · 2020: $1,027 · 2021: $1,291 · 2022: $716 · 2023: $859 · 2024: $733 · 2025: $877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,469.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,808.57 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $1,332.24 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Allergan, INC. | $411.90 | 2019-2020 | |
| Novo Nordisk INC | $315.29 | 2019-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $305.01 | 2019-2025 | |
| Glaxosmithkline, LLC. | $253.06 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Eisai INC. | $204.99 | 2020-2024 | |
| Janssen Pharmaceuticals, INC | $179.73 | 2019-2022 | |
| Lilly USA, LLC | $166.73 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $131.16 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amgen INC. | $115.46 | 2019-2025 | Otezla, Repatha, Repatha |
| Kowa Pharmaceuticals America, INC. | $90.21 | 2019-2021 | |
| Astellas Pharma US INC | $86.63 | 2021-2025 | Veozah |
| Exact Sciences Corporation | $85.34 | 2023-2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $81.54 | 2021-2023 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Willard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.